Imerys (NK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
8 Jul, 2026Opening remarks and agenda
The meeting was opened with introductions of key executives and board members, confirmation of legal formalities, and appointment of scrutineers for voting.
The agenda, draft resolutions, and voting procedures were outlined, with confirmation of quorum and availability of required documents.
Financial performance review
2025 revenue was €3.384 billion, stable year-over-year, with adjusted EBITDA at €546 million, reflecting strong pricing and cost control despite adverse forex effects.
Net income was negative due to a €467 million goodwill impairment in the RAC segment, but cash flow remained positive before strategic CapEx.
Free cash flow before strategic CapEx was €127 million; after CapEx, €78 million, mainly for lithium projects.
Net financial debt increased slightly, but investment-grade ratings were confirmed; no major strategic investments are planned for 2026.
Q1 2026 saw revenue of €835 million (+0.7% like-for-like) and adjusted EBITDA of €118 million (+4% at constant rates), with strong cost control and operational execution.
Board and executive committee updates
New CFO Pierre Lebreuil was introduced, bringing 20 years of company experience.
Johannes Huth and Michael Ogrinz were presented as new board members, with their appointments ratified.
Annette Messemer and Ian Gallienne stepped down from the board, with acknowledgments for their service.
Fatima Bensif joined as employee representative director.
Latest events from Imerys
- Solid organic growth, margin expansion, and strong ESG progress despite non-cash net loss.NK
H2 20249 Jul 2026 - All resolutions passed, with strong 2024 results, higher dividend, and strategic progress.NK
AGM 20258 Jul 2026 - H1 2024 adjusted EBITDA rose 11% to €384 million, margin 20%, with strong net income growth.NK
H1 20248 Jul 2026 - Q1 2026 saw modest growth and margin gains, offset by FX and restructuring impacts.NK
Q1 202629 Apr 2026 - Stable 2025 results, major goodwill impairment, and cost savings plus lithium investment ahead.NK
Q4 202520 Feb 2026 - Nine-month EBITDA margin rose to 19.2% as full-year guidance is confirmed.NK
Q3 202417 Jan 2026 - Organic growth and sustainability progress offset margin pressure from joint venture declines.NK
Q1 202524 Dec 2025 - Stable H1 2025 sales and EBITDA, but net income fell; full-year EBITDA guidance reaffirmed.NK
Q2 202516 Nov 2025 - Revenue down 0.7% YTD; cost controls and strategic growth moves support profitability.NK
Q3 20251 Nov 2025